TrialPath
Multiple sclerosis · San Diego

Multiple sclerosis clinical trials in San Diego

4 recruiting multiple sclerosis studies within range of San Diego. Click any trial for full eligibility criteria and contact info.

AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

NCT06665165 · ALS
Recruiting

This study is a placebo-controlled Phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide (ASO) AMX0114 in adult participants with amyotrophic lateral sclerosis (ALS).

PhasePhase 1
TypeInterventional
Age18 Years
WhereLa Jolla, California, United States + 13 more
SponsorAmylyx Pharmaceuticals Inc.
▾Tap for details
Apply

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

Recruiting

The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS. The main questions the trial aims to answer are the following: * Is TRX319 safe when administered to patients with progressive forms of MS? * At what dose does TRX319 work the best to treat participants with primary and or secondary progressive MS? * Is pre-conditioning (with Bendamustine) needed to allow TRX319 to better treat participants with primary and/or secondary progressive MS? Participants will be asked to be on study for up 1 year and may receive up to 3 total administrations of TRX319. While on study, participants will have blood tests and other assessments (MRI scans and lumbar punctures) done to understand the safety of TRX319 and how it may benefit their multiple sclerosis.

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years – 65 Years
WhereLa Jolla, California, United States + 7 more
SponsorTr1X, Inc.
▾Tap for details
Apply

Kesimpta (Ofatumumab) Pregnancy Registry

NCT05634967 · Multiple Sclerosis, Pregnancy
Recruiting

The Kesimpta Pregnancy Registry is an observational, exposure cohort designed study to examine pregnancy and infant outcomes in women and infants who are exposed to Kesimpta (ofatumumab) during pregnancy to treat MS.

Phase—
TypeObservational
Age18 Years – 100 Years
WhereLa Jolla, California, United States
SponsorNovartis Pharmaceuticals
▾Tap for details
Apply

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

Recruiting

The purpose of this study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this study. This research will investigate if PHENOGENE-1A can help people with ALS by measuring their function using the ALS Functional Rating Scale Revised (ALSFRS-R), measuring lung function using pulmonary function tests (PFTs), such as forced vital capacity (FVC), and measuring neuro-inflammatory biomarkers in the blood.

PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereScottsdale, Arizona, United States + 21 more
SponsorPhenoNet, Inc.
▾Tap for details
Apply